Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EBP | Q15125 | 2/20 | 0.43 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.43 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.43 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.43 |
| ▸ | DPP4 | P27487 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | EBPL | Q9BY08 | 1/20 | 0.39 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6095711 | 0.92 | MCHR1 (0.46) | EBPSIGMAR1TMEM97MCHR1DPP4 | |
| SCHEMBL2961184 | 0.90 | EBP (0.43) | EBPSIGMAR1TMEM97MCHR1DPP4 | |
| SCHEMBL6988443 | 0.87 | EBP (0.53) | EBPSIGMAR1TMEM97MCHR1EBPL | |
| SCHEMBL5965403 | 0.87 | MCHR1 (0.42) | EBPSIGMAR1TMEM97MCHR1DPP4 | |
| SCHEMBL5965719 | 0.87 | SIGMAR1 (0.41) | EBPSIGMAR1TMEM97MCHR1DPP4 | |
| SCHEMBL6995646 | 0.84 | DRD3 (0.56) | TMEM97MCHR1TSHRRAB9A | |
| SCHEMBL6733799 | 0.83 | FAAH (0.47) | MCHR1ALDH1A1KDM4E | |
| SCHEMBL7027091 | 0.82 | MCHR1 (0.49) | EBPSIGMAR1TMEM97MCHR1HTT | |
| SCHEMBL6997410 | 0.82 | EBP (0.45) | EBPSIGMAR1TMEM97MCHR1HTT | |
| SCHEMBL7244532 | 0.81 | KMT2A (0.45) | MCHR1DPP4ALDH1A1KDM4EABCB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030212095-A1 | New bispidine compounds and their use in the treatment of cardiac arrhythmias | ASTRAZENECA AB (SE) | 2003-11-13 | — | — | US | disclosed |
| EP-1301510-A1 | NEW BISPIDINE COMPOUNDS AND THEIR USE IN THE TREATMENT OF CARDIAC ARRHYTHMIAS | AstraZeneca AB (SE) | 2003-04-16 | — | — | EP | disclosed |
| WO-2002004446-A1 | NEW BISPIDINE COMPOUNDS AND THEIR USE IN THE TREATMENT OF CARDIAC ARRHYTHMIAS | ASTRAZENECA AB (SE) | 2002-01-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030212095-A1 | New bispidine compounds and their use in the treatment of cardiac arrhythmias | KCNH1, LBR, CACNA1E | EBP 655/4885SIGMAR1 294/4885TMEM97 722/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.